REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the ‘135 Patent). The PTAB’s decision invalidates all claims …
The post Coherus BioSciences Prevails in ‘135 IPR Decision appeared first on ForexTV.
May 17, 2017 at 04:34AM
from Nasdaq NewsFeed
No comments:
Post a Comment